Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

Rudolph E. Falk; Frederick L. Moffat; Margaret Lawler; John Heine; Leonard Makowka; Judith A. Falk

doi:10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

Rudolph E. Falk, Frederick L. Moffat, Margaret Lawler, John Heine, Leonard Makowka, Judith A. Falk

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

Original language	English (US)
Pages (from-to)	685-688
Number of pages	4
Journal	Cancer
Volume	57
Issue number	3
DOIs	https://doi.org/10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X
State	Published - Feb 1 1986
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

Cite this

@article{c0d01ba1340f4fecb313f53049fd72e1,

title = "Combination therapy for resectable and unresectable adenocarcinoma of the pancreas",

abstract = "The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.",

author = "Falk, {Rudolph E.} and Moffat, {Frederick L.} and Margaret Lawler and John Heine and Leonard Makowka and Falk, {Judith A.}",

year = "1986",

month = feb,

day = "1",

doi = "10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X",

language = "English (US)",

volume = "57",

pages = "685--688",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

AU - Falk, Rudolph E.

AU - Moffat, Frederick L.

AU - Lawler, Margaret

AU - Heine, John

AU - Makowka, Leonard

AU - Falk, Judith A.

PY - 1986/2/1

Y1 - 1986/2/1

N2 - The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

AB - The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

UR - http://www.scopus.com/inward/record.url?scp=0022636445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022636445&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

DO - 10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

M3 - Article

C2 - 3943007

AN - SCOPUS:0022636445

VL - 57

SP - 685

EP - 688

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -

Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this